about
Oral fumaric acid esters for psoriasisInterventions to promote informed consent for patients undergoing surgical and other invasive healthcare proceduresAspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published StudiesDevelopment and Delivery of a Physical Activity Intervention for People With Huntington Disease: Facilitating Translation to Clinical Practice.Oral fumaric acid esters for psoriasis: abridged Cochrane systematic review including GRADE assessmentsEffects of internet-based training on antibiotic prescribing rates for acute respiratory-tract infections: a multinational, cluster, randomised, factorial, controlled trialEvaluating cutpoints for the MHI-5 and MCS using the GHQ-12: a comparison of five different methods.Reducing the Hypomania Checklist (HCL-32) to a 16-item version.Supporting physical activity engagement in people with Huntington's disease (ENGAGE-HD): study protocol for a randomized controlled feasibility trialAre patient views about antibiotics related to clinician perceptions, management and outcome? A multi-country study in outpatients with acute cough.A feasibility randomised controlled trial of a motivational interviewing-based intervention for weight loss maintenance in adults.Clinical predictors of antibiotic prescribing for acutely ill children in primary care: an observational studyAn evaluation of the effectiveness of a multi-modal intervention in frail and pre-frail older people with type 2 diabetes--the MID-Frail study: study protocol for a randomised controlled trial.Mechanisms of change within motivational interviewing in relation to health behaviors outcomes: a systematic review.Unrecognised bipolar disorder in primary care patients with depression.A randomized feasibility study of a 12-week community-based exercise program for people with Huntington's disease.Cohort profile: the Caerphilly health and social needs electronic cohort study (E-CATALyST).Task-specific training in Huntington disease: a randomized controlled feasibility trial.Exercise testing and training in people with Huntington's disease.Treatment of acute cough/lower respiratory tract infection by antibiotic class and associated outcomes: a 13 European country observational study in primary care.Variation in family physicians’ recording of auscultation abnormalities in patients with acute cough is not explained by case mix. A study from 12 European networksAntibiotica voor acute hoest: het voorschrijfgedrag van huisartsen in dertien Europese landenAcceptability and Feasibility of Implementing Accelorometry-Based Activity Monitors and a Linked Web Portal in an Exercise Referral Scheme: Feasibility Randomized Controlled Trial
P50
Q24187957-37513B7F-2ADA-48DF-8351-B8B8CEADCADCQ24201313-459AE7BA-91B1-49F4-B38F-9B81F2F3A88DQ26751511-3FE94CD1-26A2-4DAE-8F24-9E90837315A3Q27313882-C3EEF827-688F-430A-B6EB-D3025AD5EC20Q28066898-B18468CC-EB84-4F6A-9D5C-726D7257D9EEQ30554329-67DBD2C0-1654-4234-A14F-A40E44E37FB3Q33320348-AC754446-142D-498C-B9AF-A868C46CF6C6Q34096661-3AF7EEA7-1001-4E48-B85F-E28D62008D3AQ34968069-C7C66C4F-9747-4AF8-A54F-CF59A0B613E9Q35032315-8688F366-A68C-49E5-B9F6-B9E7F1E1B5B0Q35689724-7F2848DD-5AF5-46D1-95C4-7B16EFD0FDE6Q35966968-1BDBC2D2-698F-4542-8E08-9F8F96531014Q37567059-7098E9F6-7903-465F-A10A-C2755E9CBC68Q38298474-B1BD331B-0560-47C9-833A-C6C1D97D79D9Q39786578-BA6D7558-47B6-475F-A1B8-A58C29FEEF34Q40150407-32216AA1-C3DB-4DC5-BEA1-B8D2978E5A19Q42675549-D2B57EAE-55F0-4678-8118-A37F578A03D0Q45300159-14522C2C-FE73-4E50-93D9-03795DBDA427Q45301211-56A4108F-880A-4B8F-9673-A71F1965DBFBQ45573970-1660F0E8-C146-49A9-A6B1-69C7916FDCE5Q57612667-7C418736-0AD9-4BA2-A03F-9C3F5BA4B66FQ57612720-38C03790-102A-4EC3-A015-E0260480D33AQ64103599-0D6B629C-4804-4409-82F2-E0D923695CAD
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mark Kelson
@ast
Mark Kelson
@en
Mark Kelson
@es
Mark Kelson
@nl
Mark Kelson
@sl
type
label
Mark Kelson
@ast
Mark Kelson
@en
Mark Kelson
@es
Mark Kelson
@nl
Mark Kelson
@sl
altLabel
Mark Kelly
@en
prefLabel
Mark Kelson
@ast
Mark Kelson
@en
Mark Kelson
@es
Mark Kelson
@nl
Mark Kelson
@sl
P1053
E-6753-2016
P106
P1153
56400789400
P1960
280WNZwAAAAJ
P21
P31
P3829
P496
0000-0001-7744-3780